Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
about
Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An updateResistance to receptor tyrosine kinase inhibitors in solid tumors: can we improve the cancer fighting strategy by blocking autophagy?Modulation of Autophagy by Sorafenib: Effects on Treatment ResponseAutophagy in hepatocellular carcinomas: from pathophysiology to therapeutic responseThe Role of Autophagy in Hepatocellular CarcinomaAutophagy in cancerCardiomyocyte autophagy and cancer chemotherapy.Autophagy and cancer therapy.Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.Combination of wogonin and sorafenib effectively kills human hepatocellular carcinoma cells through apoptosis potentiation and autophagy inhibitionNew knowledge of the mechanisms of sorafenib resistance in liver cancerFTY720 Induces Autophagy-Associated Apoptosis in Human Oral Squamous Carcinoma Cells, in Part, through a Reactive Oxygen Species/Mcl-1-Dependent Mechanism.Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib.Autophagy promotes resistance to photodynamic therapy-induced apoptosis selectively in colorectal cancer stem-like cellsRole of autophagy in differential sensitivity of hepatocarcinoma cells to sorafenib.Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer.Small-molecule regulators of autophagy and their potential therapeutic applications.Combined efficacy of cediranib and quinacrine in glioma is enhanced by hypoxia and causally linked to autophagic vacuole accumulation.Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out.Molecular mechanisms of fenofibrate-induced metabolic catastrophe and glioblastoma cell death.Select microtubule inhibitors increase lysosome acidity and promote lysosomal disruption in acute myeloid leukemia (AML) cells.Inhibition of autophagy exerts anti-colon cancer effects via apoptosis induced by p53 activation and ER stress.Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.Using activation status of signaling pathways as mechanism-based biomarkers to predict drug sensitivityAnalysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart TissueCrizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell linesMiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.Erlotinib resistance in lung cancer: current progress and future perspectives.Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical EvidenceAutophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastomaFlavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems.Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.Functions of autophagy in normal and diseased liver.PSMD10/gankyrin induces autophagy to promote tumor progression through cytoplasmic interaction with ATG7 and nuclear transactivation of ATG7 expressionRetinoblastoma protein regulates the crosstalk between autophagy and apoptosis, and favors glioblastoma resistance to etoposide.The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapyQuinacrine synergistically enhances the antivascular and antitumor efficacy of cediranib in intracranial mouse gliomaSurvival or death: disequilibrating the oncogenic and tumor suppressive autophagy in cancer.Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMBAn artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells.
P2860
Q24619987-72C8E4C3-C442-49B9-AD0C-8F4A134ACF27Q26739760-577D92DD-E073-42E4-B565-328BABEBB507Q26745320-9EC6B622-42BA-4EC9-8D3A-3E72DC44275AQ26767245-229BBB33-A274-4C1F-BBA8-2CA048DE1B54Q26777419-6FA072C6-7FB7-4E5D-9183-BA4E80E3FD17Q26999216-0F5253DA-DF59-4066-8506-4B2802BE4E0FQ33573823-7BF9EE2C-1411-4017-8E60-7007D273F20EQ33584607-5F583E82-57A8-44B7-B12A-8BA2D4E7D006Q33684043-A241D497-D680-4A82-A47D-5D6A6A3279ACQ33751271-18B61592-4763-4E3F-8D94-A5E9EA1CEEE7Q33759933-1F7F4F19-A334-4B91-AF61-75DDB9B5ABC7Q33912023-D55F0F5F-4A5D-4AAB-BE40-8890883D58B3Q34366102-51A1A543-C521-41F5-BB2F-5E011C2EA59AQ34373067-40118A59-90F7-414E-8B8C-E8A968CF4EDEQ34404406-570FE127-1669-4C1F-89F6-1D34713C391EQ34465240-A4E0599E-416D-4B34-A675-51C686207FDFQ34660074-D3165C89-B7C4-47E3-BED3-5FC816365AEEQ34662536-C00DF496-47AC-405E-AD3F-437A5AC96FAAQ34728237-A4A83CFF-F0FA-46FB-87C8-A2143347CAC8Q34968487-ED007F03-FBBA-4FA6-B8D1-29DEB3D69A41Q35592507-8F8A8183-631F-42EB-92FC-85BD153CC1B0Q35819410-85F7B273-E376-4591-87DE-2CEDADDA92B1Q35856250-63D74ABD-9052-4A52-9FC0-2CB128014561Q36382520-B664EE5C-E412-42FA-8BB4-77913B492B99Q36541236-A15E6CBA-3674-4768-9FCB-A03341993A58Q36545596-F47F53E1-FF3C-4257-BB13-1B6B80BCD12FQ36557155-3987DC25-065A-447A-B7A2-D4758899B246Q36605522-3CF494F9-08F0-4066-BE46-73349970A04FQ36675015-2B542B9B-E061-4113-A5E3-8DEDF72FD064Q37003332-89D7D54C-7275-4BFA-B332-481D0B84CE2EQ37061029-BCD03D44-A66E-41EE-B92B-00958165E84CQ37073574-18F9E5D1-79C5-4F87-8C79-A3407D776A0EQ37107125-E3F9BD3C-47F3-4472-AEAC-9829083AB4D3Q37141742-493B4D54-488E-4569-9662-C9B7748D170AQ37148255-C55CFA0F-2A90-4E68-B685-709960B6C3A5Q37299276-C000DEB2-450A-4D4E-BA9E-23E5B77E7A1AQ37312695-4FD5DC69-93C6-41FA-91F6-86FD578B84B1Q37577447-1A289140-118F-4879-AF74-495AD9C36FCBQ37627268-995EBAD1-A89E-42F1-8701-56D9DA1D7CEBQ37687374-BA790487-2484-4E22-BA45-E28C9B893B33
P2860
Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Inhibition of autophagy potent ...... b in hepatocellular carcinoma.
@en
Inhibition of autophagy potent ...... b in hepatocellular carcinoma.
@nl
type
label
Inhibition of autophagy potent ...... b in hepatocellular carcinoma.
@en
Inhibition of autophagy potent ...... b in hepatocellular carcinoma.
@nl
prefLabel
Inhibition of autophagy potent ...... b in hepatocellular carcinoma.
@en
Inhibition of autophagy potent ...... b in hepatocellular carcinoma.
@nl
P2093
P2860
P356
P1476
Inhibition of autophagy potent ...... b in hepatocellular carcinoma.
@en
P2093
Atsushi Hosui
Hayato Hikita
Hinako Tsunematsu
Hisashi Ishida
Naoki Hiramatsu
Naonobu Fujita
Norio Hayashi
Satoshi Shimizu
Takuya Miyagi
Tatsuya Kanto
P2860
P304
P356
10.1002/IJC.26374
P577
2011-09-12T00:00:00Z